Schwab Charles Investment Management Inc. lifted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 17.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 367,550 shares of the company’s stock after acquiring an additional 54,587 shares during the period. Schwab Charles Investment Management Inc. owned 0.30% of Ionis Pharmaceuticals worth $18,698,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of IONS. Westpac Banking Corp purchased a new position in shares of Ionis Pharmaceuticals during the 1st quarter worth $171,000. Capstone Asset Management Co. raised its holdings in shares of Ionis Pharmaceuticals by 10.3% during the 1st quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after acquiring an additional 480 shares during the period. World Asset Management Inc raised its holdings in shares of Ionis Pharmaceuticals by 27.3% during the 1st quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after acquiring an additional 1,163 shares during the period. Cheyne Capital Management UK LLP purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth $249,000. Finally, Advisors Asset Management Inc. raised its holdings in shares of Ionis Pharmaceuticals by 186.9% during the 1st quarter. Advisors Asset Management Inc. now owns 6,542 shares of the company’s stock worth $263,000 after acquiring an additional 4,262 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Shares of Ionis Pharmaceuticals, Inc. (IONS) opened at 53.88 on Thursday. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $60.01. The stock has a market capitalization of $6.70 billion, a price-to-earnings ratio of 259.04 and a beta of 3.13. The company has a 50-day moving average of $51.73 and a 200 day moving average of $48.15.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business had revenue of $104.15 million for the quarter, compared to analysts’ expectations of $93.29 million. During the same quarter last year, the company posted ($0.47) earnings per share. The business’s quarterly revenue was up 170.7% compared to the same quarter last year. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/21/schwab-charles-investment-management-inc-has-18-70-million-stake-in-ionis-pharmaceuticals-inc-ions.html.

In other news, Chairman Stanley T. Crooke sold 16,500 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $52.45, for a total value of $865,425.00. Following the transaction, the chairman now directly owns 53,014 shares in the company, valued at approximately $2,780,584.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the completion of the transaction, the senior vice president now owns 25,041 shares in the company, valued at $1,484,680.89. The disclosure for this sale can be found here. Insiders have sold 55,309 shares of company stock worth $2,997,692 over the last quarter. 1.86% of the stock is currently owned by company insiders.

Several research analysts have recently commented on IONS shares. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, July 31st. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. BMO Capital Markets reiterated a “buy” rating and set a $59.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, June 2nd. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Sunday. Finally, Barclays PLC started coverage on Ionis Pharmaceuticals in a report on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $49.31.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.